4Sc PP&E per Employee
Delisted
PP&E per Employee of 4Sc (VSC.DE) as of Aug 5, 2026.
Get this data via API
Financial Data API
PP&E per Employee
0.00EUR
Last updated:
PP&E per Employee of 4Sc is 2026 0.00 EUR. PP&E per Employee of 4Sc was 2025 46,487.18 EUR. It decreases by % lower compared to the previous year.
Access this data via the Eulerpool API
4Sc Stock analysis
What does 4Sc do? The 4Sc AG is a German biotechnology company specializing in the discovery and development of drugs for numerous indications. It was founded in 2007 and focuses on innovative immunotherapies against cancer, autoimmune diseases, and inflammation. The company's goal is to bring promising drug candidates to Phase IIb clinical trials and then license them to partner companies. Its business model involves working with academic and clinical institutions to research and expand its pipeline. The company's portfolio is divided into three main areas: oncology, autoimmune diseases, and inflammation. It develops drugs that utilize the body's immune system to target cancer cells, inhibit inflammation for autoimmune diseases, and specifically target inflammation for other conditions. Overall, 4Sc AG aims to discover and develop novel drugs that can help patients with severe medical conditions. 4Sc is one of the most popular companies on Eulerpool.
Frequently Asked Questions about 4Sc stock
On Eulerpool you can find the complete historical development of PP&E per Employee 4Sc since 2006 – with annual values, charts, and detailed analysis.
PP&E per employee measures the physical capital intensity per worker. Higher values indicate more capital-intensive operations.
PP&E per Employee's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track PP&E per Employee's 4Sc historically and in real time.
Access this data via the Eulerpool API
Workforce — 4Sc
All Key Metrics — 4Sc
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth